X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Divis Laboratories with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs MYLAN (US) - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DIVIS LABORATORIES   MYLAN
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
MYLAN
Dec-14
DIVIS LABORATORIES/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1,2223,795-   
Low Rs7842,674-   
Sales per share (Unadj.) Rs153.11,299.1-  
Earnings per share (Unadj.) Rs39.9156.5-  
Cash flow per share (Unadj.) Rs44.6251.9-  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.8645.8-  
Shares outstanding (eoy) m265.47378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x6.62.5 263.1%   
Avg P/E ratio x25.120.7 121.5%  
P/CF ratio (eoy) x22.512.8 175.2%  
Price / Book Value ratio x5.05.0 99.2%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2661,223,813 21.8%   
No. of employees `0009.725.0 38.9%   
Total wages/salary Rs m4,6870-   
Avg. sales/employee Rs Th4,175.019,661.3 21.2%   
Avg. wages/employee Rs Th481.50-   
Avg. net profit/employee Rs Th1,089.32,368.5 46.0%   
INCOME DATA
Net Sales Rs m40,643491,532 8.3%  
Other income Rs m749-2,865 -26.1%   
Total revenues Rs m41,392488,667 8.5%   
Gross profit Rs m14,460122,246 11.8%  
Depreciation Rs m1,23336,101 3.4%   
Interest Rs m2321,202 0.1%   
Profit before tax Rs m13,95362,078 22.5%   
Minority Interest Rs m0-255 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,3492,610 128.3%   
Profit after tax Rs m10,60459,213 17.9%  
Gross profit margin %35.624.9 143.1%  
Effective tax rate %24.04.2 570.8%   
Net profit margin %26.112.0 216.6%  
BALANCE SHEET DATA
Current assets Rs m40,105432,122 9.3%   
Current liabilities Rs m6,595337,833 2.0%   
Net working cap to sales %82.519.2 429.8%  
Current ratio x6.11.3 475.5%  
Inventory Days Days11978 151.9%  
Debtors Days Days81107 75.2%  
Net fixed assets Rs m19,995113,715 17.6%   
Share capital Rs m53117,382 3.1%   
"Free" reserves Rs m53,0430-   
Net worth Rs m53,574244,340 21.9%   
Long term debt Rs m0365,020 0.0%   
Total assets Rs m61,585984,179 6.3%  
Interest coverage x618.43.9 15,743.8%   
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x0.70.5 132.1%   
Return on assets %17.38.2 211.2%  
Return on equity %19.824.2 81.7%  
Return on capital %26.113.6 191.5%  
Exports to sales %00-   
Imports to sales %25.20-   
Net fx Rs m24,9850-   
CASH FLOW
From Operations Rs m11,49364,612 17.8%  
From Investments Rs m-11,372-50,955 22.3%  
From Financial Activity Rs m-93-17,025 0.5%  
Net Cashflow Rs m28-3,368 -0.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 63.67 Rs / USD

Compare DIVIS LABORATORIES With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare DIVIS LABORATORIES With: GSK PHARMA  CIPLA  AJANTA PHARMA  FDC LTD.  LUPIN LTD  



Today's Market

Indian Share Markets Trade Flat; TCS Surges 3.5%(01:30 pm)

Indian share markets continued to trade on a flat note in the noon session. Gains are largely seen in software stocks, bank stocks and capital goods' stocks.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 16, 2018 01:43 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS